Dilated Cardiomyopathy Therapeutic Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast – 2022 to 2028

The Global Dilated Cardiomyopathy Therapeutic Market estimated at US$304.5 Million in the year 2020, is projected to reach a revised size of US$411.6 Million by 2028, growing at a CAGR of 4% over the forecast period 2022-2028.

Dilated cardiomyopathy is an umbrella term for heart muscle disease and is considered a fatal heart disorder. It is usually characterized by left and right ventricular dilatation and decreased myocardial contractility. Dilated cardiomyopathy (DCM) is an abnormality of the heart muscle that usually begins in the heart’s main pump chamber (the left ventricle). The ventricles become weak and dilate, unable to pump blood. A common cause of heart failure is that the heart cannot supply enough blood to the body, and dilated cardiomyopathy also causes an irregular heartbeat (arrhythmia), blood clots, or sudden death. People of all ages, including infants and young children, are affected by DCM, but it is most common in men between the ages of 20 and 50.

Market Segments

By Drug Class

• Aldosterone antagonists
• Angiotensin-converting enzyme (ACE) inhibitors
• Angiotensin II receptor blockers (ARBs)
• Beta-blockers

By Pipeline Drugs

• ARRY-797
• ixCELL-DCM
• MYDICAR
• OR-1
• CAP-1002

 Key Players

• Array BioPharma Inc.
• AstraZeneca plc
• Celladon Corporation
• GlaxoSmithKline plc
• Janssen Pharmaceuticals Inc.
• Merck & Co. Inc.
• Novartis International AG
• Pfizer Inc.
• Sanofi S.A
• Teva Pharmaceutical Industries Ltd
• Vericel Corporation

Scope of the Report

The research study analyzes the global Dilated Cardiomyopathy Therapeutic industry from 360-degree analysis of the market thoroughly delivering insights into the market for better business decisions, considering multiple aspects some of which are listed below as:

Recent Developments

o Market Overview and growth analysis
o Import and Export Overview
o Volume Analysis
o Current Market Trends and Future Outlook
o Market Opportunistic and Attractive Investment Segment

Geographic Coverage

o North America Market Size and/or Volume
o Latin America Market Size and/or Volume
o Europe Market Size and/or Volume
o Asia-Pacific Market Size and/or Volume
o Rest of the world Market Size and/or Volume

Key Questions Answered by Dilated Cardiomyopathy Therapeutic Market Report

1. What was the Dilated Cardiomyopathy Therapeutic Market size in 2020 and 2021; what are the estimated growth trends and market forecast (2022-2028).

2. What will be the CAGR of Dilated Cardiomyopathy Therapeutic Market during the forecast period (2022-2028)?
3. Which segments (product type/applications/end-user) were most attractive for investments in 2022? How these segments are expected to grow during the forecast period (2022-2028).
4. Which manufacturer/vendor/players in the Dilated Cardiomyopathy Therapeutic Market was the market leader in 2020?
5. Overview on the existing product portfolio, products in the pipeline, and strategic initiatives taken by key vendors in the market.